JPMorgan Chase & Co. Boosts Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $38.00

Syndax Pharmaceuticals (NASDAQ:SNDX) had its target price upped by stock analysts at JPMorgan Chase & Co. from $33.00 to $38.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 151.66% from the company’s current price.

A number of other analysts also recently issued reports on the stock. UBS Group initiated coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 target price for the company. HC Wainwright boosted their price objective on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the stock a “buy” rating in a research note on Monday. Stifel Nicolaus boosted their price target on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Citigroup increased their price objective on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, The Goldman Sachs Group raised their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $37.64.

Syndax Pharmaceuticals Price Performance

NASDAQ:SNDX traded down $0.85 during trading hours on Thursday, reaching $15.10. 911,152 shares of the company were exchanged, compared to its average volume of 1,148,398. Syndax Pharmaceuticals has a 52-week low of $15.00 and a 52-week high of $25.34. The stock has a 50 day simple moving average of $18.71 and a 200 day simple moving average of $20.08. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -4.41 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same quarter in the previous year, the business posted ($0.73) EPS. On average, analysts predict that Syndax Pharmaceuticals will post -3.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Iron Triangle Partners LP acquired a new stake in shares of Syndax Pharmaceuticals in the first quarter valued at $23,159,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in shares of Syndax Pharmaceuticals during the third quarter valued at approximately $15,165,000. Eventide Asset Management LLC purchased a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter valued at approximately $15,150,000. First Turn Management LLC acquired a new stake in Syndax Pharmaceuticals during the 2nd quarter valued at $13,147,000. Finally, Vanguard Group Inc. increased its holdings in shares of Syndax Pharmaceuticals by 13.6% in the 1st quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock valued at $117,262,000 after purchasing an additional 591,631 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).